{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:40:45Z","timestamp":1773193245939,"version":"3.50.1"},"reference-count":236,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2021,3,22]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Many antibiotics have a high potential for interactions with drugs, as a perpetrator\nand\/or victim, in critically ill patients, and particularly in sepsis patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> The aim of this review is to summarize the pharmacokinetic drug-drug interaction (DDI) of 45 antibiotics\ncommonly used in sepsis care in China. Literature search was conducted to obtain human pharmacokinetics\/\ndispositions of the antibiotics, their interactions with drug-metabolizing enzymes or transporters, and their\nassociated clinical drug interactions. Potential DDI is indicated by a DDI index \u2265 0.1 for inhibition or a treatedcell\/\nuntreated-cell ratio of enzyme activity being \u2265 2 for induction.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The literature-mined information on human pharmacokinetics of the identified antibiotics and their potential\ndrug interactions is summarized.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Antibiotic-perpetrated drug interactions, involving P450 enzyme inhibition, have been reported\nfor four lipophilic antibacterials (ciprofloxacin, erythromycin, trimethoprim, and trimethoprim-sulfamethoxazole)\nand three antifungals (fluconazole, itraconazole, and voriconazole). In addition, seven hydrophilic antibacterials\n(ceftriaxone, cefamandole, piperacillin, penicillin G, amikacin, metronidazole, and linezolid) inhibit drug\ntransporters in vitro. Despite no clinical PK drug interactions with the transporters, caution is advised in the use\nof these antibacterials. Eight hydrophilic antibiotics (all \u03b2-lactams; meropenem, cefotaxime, cefazolin, piperacillin,\nticarcillin, penicillin G, ampicillin, and flucloxacillin), are potential victims of drug interactions due to\ntransporter inhibition. Rifampin is reported to perpetrate drug interactions by inducing CYP3A or inhibiting\nOATP1B; it is also reported to be a victim of drug interactions, due to the dual inhibition of CYP3A4 and OATP1B\nby indinavir. In addition, three antifungals (caspofungin, itraconazole, and voriconazole) are reported to be\nvictims of drug interactions because of P450 enzyme induction. Reports for other antibiotics acting as victims\nin drug interactions are scarce.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200221666200929115117","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T14:19:03Z","timestamp":1601389143000},"page":"5-23","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetic Drug-drug Interaction of Antibiotics Used in Sepsis Care in China"],"prefix":"10.2174","volume":"22","author":[{"given":"Xuan","family":"Yu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixuan","family":"Chu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaya","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Cheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/978-1-4419-0840-7_24","author":"Greenblatt D.J.","year":"2010","unstructured":"Greenblatt D.J.; von Moltke L.L.; Eds.; Springer: New York, Enzyme and transporter-based drug-drug interactions: progress and future challenges 2010,625-649","journal-title":"Enzyme and transporter-based drug-drug interactions: progress and future challenges"},{"key":"ref=2","doi-asserted-by":"publisher","author":"Greenblatt D.J.","unstructured":"Greenblatt D.J.;  Introduction to drug-drug interactions. Drug Interaction in\nInfectious Diseases, 3 ed; Piscitelli, S.C.; Rodvold, K.A.; Pai, M.P. Ed;\nSpringer: New York 2011. pp. 1-10.","DOI":"10.1007\/978-1-61779-213-7_1"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1002\/jps.24113","volume":"103","author":"Shao J.","year":"2014","unstructured":"Shao J.; Markowitz J.S.; Bei D.; An G.; Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci 2014,103(12),3810-3833","journal-title":"J Pharm Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.apsb.2019.06.003","volume":"9","author":"Li J.","year":"2019","unstructured":"Li J.; Olaleye O.E.; Yu X.; Jia W.W.; Yang J.L.; Lu C.; Liu S.Q.; Yu J.J.; Duan X.N.; Wang Y.Y.; Dong K.; He R.R.; Cheng C.; Li C.; High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing injection and antibiotics. Acta Pharm Sin B 2019,9,1035-1049","journal-title":"Acta Pharm Sin B"},{"key":"ref=5","unstructured":"U.S. Food and Drug Administration. In vitro drug interaction studies \u2013 cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. Available at:  https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM581965.pdf"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1517\/17425255.2013.781582","volume":"9","author":"Bloomer J.","year":"2013","unstructured":"Bloomer J.; Derimanov G.; Dumont E.; Ellens H.; Matheny C.; Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations. Expert Opin Drug Metab Toxicol 2013,9(6),737-751","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.mcna.2006.06.008","volume":"90","author":"Pai M.P.","year":"2006","unstructured":"Pai M.P.; Momary K.M.; Rodvold K.A.; Antibiotic drug interactions. Med Clin North Am 2006,90(6),1223-1255","journal-title":"Med Clin North Am"},{"key":"ref=8","unstructured":"Statistics Drug Bank"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1001\/jama.1990.03450210088038","volume":"264","author":"Monahan B.P.","year":"1990","unstructured":"Monahan B.P.; Ferguson C.L.; Killeavy E.S.; Lloyd B.K.; Troy J.; Cantilena L.R.; Torsades de pointes occurring in association with terfenadine use. JAMA 1990,264(21),2788-2790","journal-title":"JAMA"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/jama.280.2.157","volume":"280","author":"Mullins M.E.","year":"1998","unstructured":"Mullins M.E.; Horowitz B.Z.; Linden D.H.; Smith G.W.; Norton R.L.; Stump J.; Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998,280(2),157-158","journal-title":"JAMA"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1001\/jama.283.17.2228-JFD00003-2-1","volume":"283","author":"Henney J.E.","year":"2000","unstructured":"Henney J.E.; Withdrawal of troglitazone and cisapride. JAMA 2000,283,2228","journal-title":"JAMA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jama.2016.0288","volume":"315","author":"Seymour C.W.","year":"2016","unstructured":"Seymour C.W.; Liu V.X.; Iwashyna T.J.; Brunkhorst F.M.; Rea T.D.; Scherag A.; Rubenfeld G.; Kahn J.M.; Shankar-Hari M.; Singer M.; Deutschman C.S.; Escobar G.J.; Angus D.C.; Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016,315(8),762-774","journal-title":"JAMA"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jama.2016.0289","volume":"315","author":"Shankar-Hari M.","year":"2016","unstructured":"Shankar-Hari M.; Phillips G.S.; Levy M.L.; Seymour C.W.; Liu V.X.; Deutschman C.S.; Angus D.C.; Rubenfeld G.D.; Singer M.; Developing a newdefinition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA Sepsis Definitions Task Force2016,315(8),775-787","journal-title":"JAMA"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"Singer M.","year":"2016","unstructured":"Singer M.; Deutschman C.S.; Seymour C.W.; Shankar-Hari M.; Annane D.; Bauer M.; Bellomo R.; Bernard G.R.; Chiche J.D.; Coopersmith C.M.; Hotchkiss R.S.; Levy M.M.; Marshall J.C.; Martin G.S.; Opal S.M.; Rubenfeld G.D.; van der Poll T.; Vincent J.L.; Angus D.C.; The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016,315(8),801-810","journal-title":"JAMA"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2017.36","volume":"17","author":"van der Poll T.","year":"2017","unstructured":"van der Poll T.; van de Veerdonk F.L.; Scicluna B.P.; Netea M.G.; The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol 2017,17(7),407-420","journal-title":"Nat Rev Immunol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.immuni.2014.04.001","volume":"40","author":"Deutschman C.S.","year":"2014","unstructured":"Deutschman C.S.; Tracey K.J.; Sepsis: current dogma and new perspectives. Immunity 2014,40(4),463-475","journal-title":"Immunity"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1208623","volume":"369","author":"Angus D.C.","year":"2013","unstructured":"Angus D.C.; van der Poll T.; Severe sepsis and septic shock. N Engl J Med 2013,369(9),840-851","journal-title":"N Engl J Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(15)70112-X","volume":"15","author":"Cohen J.","year":"2015","unstructured":"Cohen J.; Vincent J.L.; Adhikari N.K.; Machado F.R.; Angus D.C.; Calandra T.; Jaton K.; Giulieri S.; Delaloye J.; Opal S.; Tracey K.; van der Poll T.; Pelfrene E.; Sepsis: a roadmap for future research. Lancet Infect Dis 2015,15(5),581-614","journal-title":"Lancet Infect Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jama.2017.0131","volume":"317","author":"Howell M.D.","year":"2017","unstructured":"Howell M.D.; Davis A.M.; Management of sepsis and septic shock. JAMA 2017,317(8),847-848","journal-title":"JAMA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nrd4368","volume":"13","author":"Fink M.P.","year":"2014","unstructured":"Fink M.P.; Warren H.S.; Strategies to improve drug development for sepsis. Nat Rev Drug Discov 2014,13(10),741-758","journal-title":"Nat Rev Drug Discov"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"Rhodes A.","year":"2017","unstructured":"Rhodes A.; Evans L.E.; Alhazzani W.; Levy M.M.; Antonelli M.; Ferrer R.; Kumar A.; Sevransky J.E.; Sprung C.L.; Nunnally M.E.; Rochwerg B.; Rubenfeld G.D.; Angus D.C.; Annane D.; Beale R.J.; Bellinghan G.J.; Bernard G.R.; Chiche J.D.; Coopersmith C.; De Backer D.P.; French C.J.; Fujishima S.; Gerlach H.; Hidalgo J.L.; Hollenberg S.M.; Jones A.E.; Karnad D.R.; Kleinpell R.M.; Koh Y.; Lisboa T.C.; Machado F.R.; Marini J.J.; Marshall J.C.; Mazuski J.E.; McIntyre L.A.; McLean A.S.; Mehta S.; Moreno R.P.; Myburgh J.; Navalesi P.; Nishida O.; Osborn T.M.; Perner A.; Plunkett C.M.; Ranieri M.; Schorr C.A.; Seckel M.A.; Seymour C.W.; Shieh L.; Shukri K.A.; Simpson S.Q.; Singer M.; Thompson B.T.; Townsend S.R.; Van der Poll T.; Vincent J.L.; Wiersinga W.J.; Zimmerman J.L.; Dellinger R.P.; Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. Intensive Care Med 2017,43(3),304-377","journal-title":"Intensive Care Med"},{"key":"ref=22","first-page":"26","volume":"3","author":"Wang H.L.","year":"2017","unstructured":"Wang H.L.; Zhang Z.D.; Huang W.; Surviving sepsis campaign: international guidelines for management of sepsis and septic shock (2016): interpretation and expectation. Chin J Crit Care Intensive Care Med 2017,3,26-32","journal-title":"Chin J Crit Care Intensive Care Med"},{"key":"ref=23","first-page":"18","volume":"3","author":"Xie J.F.","year":"2017","unstructured":"Xie J.F.; Qiu H.B.; Surviving sepsis campaign: international guideline for management of sepsis and septic shock (2016): progress and comment. Chin J Crit Care Intensive Care Med 2017,3,18-25","journal-title":"Chin J Crit Care Intensive Care Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/phar.1395","volume":"34","author":"Uijtendaal E.V.","year":"2014","unstructured":"Uijtendaal E.V.; van Harssel L.L.; Hugenholtz G.W.; Kuck E.M.; Zwart- van Rijkom J.E.; Cremer O.L.; Egberts T.C.; Analysis of potential drug- drug interactions in medical intensive care unit patients. Pharmacotherapy 2014,34(3),213-219","journal-title":"Pharmacotherapy"},{"key":"ref=25","first-page":"25","volume":"8","author":"Pereira J.M.","year":"2013","unstructured":"Pereira J.M.; Paiva J.A.; Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol 2013,8(1),25-38","journal-title":"Curr Clin Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.2042-7174.2012.00221.x","volume":"20","author":"Smithburger P.L.","year":"2012","unstructured":"Smithburger P.L.; Kane-Gill S.L.; Seybert A.L.; Drug-drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. Int J Pharm Pract 2012,20(6),402-408","journal-title":"Int J Pharm Pract"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2165\/00003088-200140110-00004","volume":"40","author":"Pea F.","year":"2001","unstructured":"Pea F.; Furlanut M.; Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001,40(11),833-868","journal-title":"Clin Pharmacokinet"},{"key":"ref=28","unstructured":"Pharmapendium, Reed Elsevier Properties SA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(85)90101-9","volume":"78","author":"Drusano G.L.","year":"1985","unstructured":"Drusano G.L.; Standiford H.C.; Pharmacokinetic profile of imipenem\/cilastatin in normal volunteers. Am J Med 1985,78(6A),47-53","journal-title":"Am J Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/00003088-200544050-00007","volume":"44","author":"Novelli A.","year":"2005","unstructured":"Novelli A.; Adembri C.; Livi P.; Fallani S.; Mazzei T.; De Gaudio A.R.; Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005,44(5),539-549","journal-title":"Clin Pharmacokinet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2174\/187231208786734049","volume":"2","author":"Nakamura Y.","year":"2008","unstructured":"Nakamura Y.; Nakahira K.; Mizutani T.; Decreased valproate level caused by VPA-glucuronidase inhibition by carbapenem antibiotics. Drug Metab Lett 2008,2(4),280-285","journal-title":"Drug Metab Lett"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/FTD.0b013e318260f7b3","volume":"34","author":"Park M.K.","year":"2012","unstructured":"Park M.K.; Lim K.S.; Kim T.E.; Han H.K.; Yi S.J.; Shin K.H.; Cho J.Y.; Shin S.G.; Jang I.J.; Yu K.S.; Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: overview of 6 cases. Ther Drug Monit 2012,34(5),599-603","journal-title":"Ther Drug Monit"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/FTD.0000000000000316","volume":"38","author":"Wu C.C.","year":"2016","unstructured":"Wu C.C.; Pai T.Y.; Hsiao F.Y.; Shen L.J.; Wu F.L.; The effect of different carbapenem antibiotics (ertapenem, imipenem\/cilastatin, and meropenem) on serum valproic acid concentrations. Ther Drug Monit 2016,38(5),587-592","journal-title":"Ther Drug Monit"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0014-2999(01)00962-1","volume":"419","author":"Takeda M.","year":"2001","unstructured":"Takeda M.; Narikawa S.; Hosoyamada M.; Cha S.H.; Sekine T.; Endou H.; Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol 2001,419(2-3),113-120","journal-title":"Eur J Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2133\/dmpk.22.41","volume":"22","author":"Shibayama T.","year":"2007","unstructured":"Shibayama T.; Sugiyama D.; Kamiyama E.; Tokui T.; Hirota T.; Ikeda T.; Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab Pharmacokinet 2007,22(1),41-47","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=36","year":"2016","unstructured":"Drug Information: Merrem (meropenem for injection) U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2016"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1128\/AAC.46.11.3506-3511.2002","volume":"46","author":"Majumdar A.K.","year":"2002","unstructured":"Majumdar A.K.; Musson D.G.; Birk K.L.; Kitchen C.J.; Holland S.; McCrea J.; Mistry G.; Hesney M.; Xi L.; Li S.X.; Haesen R.; Blum R.A.; Lins R.L.; Greenberg H.; Waldman S.; Deutsch P.; Rogers J.D.; Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002,46(11),3506-3511","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ijantimicag.2008.10.005","volume":"33","author":"Brink A.J.","year":"2009","unstructured":"Brink A.J.; Richards G.A.; Schillack V.; Kiem S.; Schentag J.; Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents 2009,33(5),432-436","journal-title":"Int J Antimicrob Agents"},{"key":"ref=39","year":"2014","unstructured":"Drug Information: Invanz (ertapenem for injection) U.S. Food and Drug Administration2014"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"ii23","DOI":"10.1093\/jac\/dkh205","volume":"53","author":"Nix D.E.","year":"2004","unstructured":"Nix D.E.; Majumdar A.K.; DiNubile M.J.; Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004,53(Suppl. 2),ii23-ii28","journal-title":"J Antimicrob Chemother"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1055\/s-0033-1341498","volume":"63","author":"Liu Y.","year":"2013","unstructured":"Liu Y.; Li Z.; Yang C.; Zheng H.; Lv Y.; Chen H.; Zhang Y.; Shi S.; Tolerability and pharmacokinetics of biapenem following single and multiple intravenous administrations in healthy Chinese subjects: an open-label, randomized, single-center study. Drug Res (Stuttg) 2013,63(8),396-403","journal-title":"Drug Res (Stuttg)"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ja.2008.43","volume":"61","author":"Suyama H.","year":"2008","unstructured":"Suyama H.; Ikawa K.; Morikawa N.; Ikeda K.; Fujiue Y.; Morikawa S.; Kaneko K.; Kuwabara M.; Yamanoue T.; Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration. Jpn J Antibiot 2008,61(5),303-313","journal-title":"Jpn J Antibiot"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.2165\/00003495-200262150-00005","volume":"62","author":"Perry C.M.","year":"2002","unstructured":"Perry C.M.; Ibbotson T.; Biapenem. Drugs 2002,62(15),2221-2234","journal-title":"Drugs"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1128\/AAC.36.3.552","volume":"36","author":"Barbhaiya R.H.","year":"1992","unstructured":"Barbhaiya R.H.; Forgue S.T.; Gleason C.R.; Knupp C.A.; Pittman K.A.; Weidler D.J.; Movahhed H.; Tenney J.; Martin R.R.; Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992,36(3),552-557","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1074\/jbc.275.3.1699","volume":"275","author":"Ganapathy M.E.","year":"2000","unstructured":"Ganapathy M.E.; Huang W.; Rajan D.P.; Carter A.L.; Sugawara M.; Iseki K.; Leibach F.H.; Ganapathy V.; beta-lactam antibiotics as substrates for OCTN2, an organic cation\/carnitine transporter. J Biol Chem 2000,275(3),1699-1707","journal-title":"J Biol Chem"},{"key":"ref=46","year":"2017","unstructured":"Drug Information: Maxipime (cefepime hydrochloride for injection) U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2017"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jac\/32.suppl_B.117","volume":"32","author":"Kieft H.","year":"1993","unstructured":"Kieft H.; Hoepelman A.I.; Knupp C.A.; van Dijk A.; Branger J.M.; Struyvenberg A.; Verhoef J.; Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother 1993,32(Suppl. B),117-122","journal-title":"J Antimicrob Chemother"},{"key":"ref=48","first-page":"543","volume":"28","author":"Zhu Z.","year":"1993","unstructured":"Zhu Z.; Wang A.X.; Li Y.; Xu X.W.; Chen L.Y.; Clinical pharmacokinetics of ceftriaxone. Chung Kuo Yao Hsueh Tsa Chih 1993,28,543-546","journal-title":"Chung Kuo Yao Hsueh Tsa Chih"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1124\/dmd.112.049312","volume":"41","author":"Grime K.","year":"2013","unstructured":"Grime K.; Paine S.W.; Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement. Drug Metab Dispos 2013,41(2),372-378","journal-title":"Drug Metab Dispos"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2174\/1389200217666160629114449","volume":"17","author":"Hua W.J.","year":"2016","unstructured":"Hua W.J.; Hua W.X.; Jian Z.; Wei P.H.; Ni L.Y.; Hua L.Y.; Wen C.D.; Ying Z.; Li C.; The role of drug transporters in the pharmacokinetics of antibiotics. Curr Drug Metab 2016,17(8),799-805","journal-title":"Curr Drug Metab"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1128\/AAC.20.5.634","volume":"20","author":"Patel I.H.","year":"1981","unstructured":"Patel I.H.; Chen S.; Parsonnet M.; Hackman M.R.; Brooks M.A.; Konikoff J.; Kaplan S.A.; Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 1981,20(5),634-641","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/jac\/47.4.421","volume":"47","author":"Joynt G.M.","year":"2001","unstructured":"Joynt G.M.; Lipman J.; Gomersall C.D.; Young R.J.; Wong E.L.; Gin T.; The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001,47(4),421-429","journal-title":"J Antimicrob Chemother"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1124\/dmd.112.048264","volume":"41","author":"Ren S.","year":"2013","unstructured":"Ren S.; Zeng J.; Mei Y.; Zhang J.Z.; Yan S.F.; Fei J.; Chen L.; Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. Drug Metab Dispos 2013,41(1),60-71","journal-title":"Drug Metab Dispos"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1248\/bpb.34.389","volume":"34","author":"Yamaguchi H.","year":"2011","unstructured":"Yamaguchi H.; Takeuchi T.; Okada M.; Kobayashi M.; Unno M.; Abe T.; Goto J.; Hishinuma T.; Shimada M.; Mano N.; Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull 2011,34(3),389-395","journal-title":"Biol Pharm Bull"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1124\/dmd.111.041731","volume":"40","author":"de Waart D.R.","year":"2012","unstructured":"de Waart D.R.; van de Wetering K.; Kunne C.; Duijst S.; Paulusma C.C.; Oude Elferink R.P.; Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos 2012,40(3),515-521","journal-title":"Drug Metab Dispos"},{"key":"ref=56","year":"2015","unstructured":"Drug Information: Rocephin (ceftriaxone sodium for injection) U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2015"},{"key":"ref=57","first-page":"65","volume":"2","author":"Li J.T.","year":"1986","unstructured":"Li J.T.; Sun Z.M.; Xu X.Y.; Huang Y.A.; Pharmacokinetic study on ceftazidime","journal-title":"Zhongguo Lin Chuang Yao Li Xue Za Zhi"},{"key":"ref=58","year":"2017","unstructured":"Drug Information: Fortaz (ceftazidime for injection) U.S. Food and Drug Administration2017"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1128\/AAC.32.1.42","volume":"32","author":"Reitberg D.P.","year":"1988","unstructured":"Reitberg D.P.; Whall T.J.; Chung M.; Blickens D.; Swarz H.; Arnold J.; Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination. Antimicrob Agents Chemother 1988,32(1),42-46","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1124\/dmd.107.019125","volume":"36","author":"Kato Y.","year":"2008","unstructured":"Kato Y.; Takahara S.; Kato S.; Kubo Y.; Sai Y.; Tamai I.; Yabuuchi H.; Tsuji A.; Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of \u03b2-lactam antibiotics. Drug Metab Dispos 2008,36(6),1088-1096","journal-title":"Drug Metab Dispos"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2133\/dmpk.DMPK-11-RG-063","volume":"26","author":"Akanuma S.","year":"2011","unstructured":"Akanuma S.; Uchida Y.; Ohtsuki S.; Kamiie J.; Tachikawa M.; Terasaki T.; Hosoya K.; Molecular-weight-dependent, anionic-substrate-preferential transport of \u03b2-lactam antibiotics via multidrug resistance-associated protein 4. Drug Metab Pharmacokinet 2011,26(6),602-611","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1128\/AAC.32.5.730","volume":"32","author":"Schwartz J.I.","year":"1988","unstructured":"Schwartz J.I.; Jauregui L.E.; Bachmann K.A.; Martin M.E.; Reitberg D.P.; Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients. Antimicrob Agents Chemother 1988,32(5),730-735","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jac\/6.suppl_A.83","volume":"6","author":"Esmieu F.","year":"1980","unstructured":"Esmieu F.; Guibert J.; Rosenkilde H.C.; Ho I.; Le Go A.; Pharmacokinetics of cefotaxime in normal human volunteers. J Antimicrob Chemother 1980,6(Suppl. A),83-92","journal-title":"J Antimicrob Chemother"},{"key":"ref=64","first-page":"433","volume":"23","author":"Qi H.M.","year":"2007","unstructured":"Qi H.M.; Wei M.; Zhao C.; Lv Y.; Zhang P.; Liu Y.; Influence of aging kidney on the pharmacokinetics of cefoperazone\/sulbactam (1:1). Zhongguo Lin Chuang Yao Li Xue Za Zhi 2007,23,433-436","journal-title":"Zhongguo Lin Chuang Yao Li Xue Za Zhi"},{"key":"ref=65","year":"2017","unstructured":"Drug Information: Cefobid (sterile cefoperazone sodium) U.S. Food and Drug Administration2017"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1002\/jps.23581","volume":"102","author":"Yee S.W.","year":"2013","unstructured":"Yee S.W.; Nguyen A.N.; Brown C.; Savic R.M.; Zhang Y.; Castro R.A.; Cropp C.D.; Choi J.H.; Singh D.; Tahara H.; Stocker S.L.; Huang Y.; Brett C.M.; Giacomini K.M.; Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). J Pharm Sci 2013,102(9),3451-3457","journal-title":"J Pharm Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1124\/mol.106.031823","volume":"71","author":"Ci L.","year":"2007","unstructured":"Ci L.; Kusuhara H.; Adachi M.; Schuetz J.D.; Takeuchi K.; Sugiyama Y.; Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol 2007,71(6),1591-1597","journal-title":"Mol Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-2999(02)01306-7","volume":"438","author":"Takeda M.","year":"2002","unstructured":"Takeda M.; Babu E.; Narikawa S.; Endou H.; Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 2002,438(3),137-142","journal-title":"Eur J Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-2999(03)01381-5","volume":"465","author":"Khamdang S.","year":"2003","unstructured":"Khamdang S.; Takeda M.; Babu E.; Noshiro R.; Onozato M.L.; Tojo A.; Enomoto A.; Huang X.L.; Narikawa S.; Anzai N.; Piyachaturawat P.; Endou H.; Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol 2003,465(1-2),1-7","journal-title":"Eur J Pharmacol"},{"key":"ref=70","year":"2015","unstructured":"Drug Information: Claforan (cefotaxime for injection) U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2015"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF00609865","volume":"12","author":"Gower P.E.","year":"1977","unstructured":"Gower P.E.; Dash C.H.; The pharmacokinetics of cefuroxime after intravenous injection. Eur J Clin Pharmacol 1977,12(3),221-227","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=72","year":"2015","unstructured":"Drug Information: Duplex (cefuroxime for injection) U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2015"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1128\/AAC.10.5.814","volume":"10","author":"Griffith R.S.","year":"1976","unstructured":"Griffith R.S.; Black H.R.; Brier G.L.; Wolny J.D.; Cefamandole: in vitro and clinical pharmacokinetics. Antimicrob Agents Chemother 1976,10(5),814-823","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/infdis\/137.Supplement.S80","volume":"137","author":"Neu H.C.","year":"1978","unstructured":"Neu H.C.; Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds J Infect Dis 1978,137,S80-87","journal-title":"J Infect Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1128\/AAC.11.2.262","volume":"11","author":"Mellin H.E.","year":"1977","unstructured":"Mellin H.E.; Welling P.G.; Madsen P.O.; Pharmacokinetics of cefamandole in patients with normal and impaired renal function. Antimicrob Agents Chemother 1977,11(2),262-266","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2165\/00003088-197702040-00002","volume":"2","author":"Craig W.A.","year":"1977","unstructured":"Craig W.A.; Welling P.G.; Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1977,2(4),252-268","journal-title":"Clin Pharmacokinet"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1093\/jac\/31.6.1009","volume":"31","author":"Brown G.","year":"1993","unstructured":"Brown G.; Zemcov S.J.; Clarke A.M.; Effect of probenecid on cefazolin serum concentrations. J Antimicrob Chemother 1993,31(6),1009-1011","journal-title":"J Antimicrob Chemother"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1124\/dmd.116.074294","volume":"45","author":"Mathialagan S.","year":"2017","unstructured":"Mathialagan S.; Piotrowski M.A.; Tess D.A.; Feng B.; Litchfield J.; Varma M.V.; Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor approach. Drug Metab Dispos 2017,45(4),409-417","journal-title":"Drug Metab Dispos"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jac\/31.suppl_A.39","volume":"31","author":"S\u00f6rgel F.","year":"1993","unstructured":"S\u00f6rgel F.; Kinzig M.; The chemistry, pharmacokinetics and tissue distribution of piperacillin\/tazobactam. J Antimicrob Chemother 1993,31(Suppl. A),39-60","journal-title":"J Antimicrob Chemother"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1517\/17425255.2010.506187","volume":"6","author":"Hayashi Y.","year":"2010","unstructured":"Hayashi Y.; Roberts J.A.; Paterson D.L.; Lipman J.; Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol 2010,6(8),1017-1031","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.12.037","volume":"537","author":"Wen S.","year":"2018","unstructured":"Wen S.; Wang C.; Duan Y.; Huo X.; Meng Q.; Liu Z.; Yang S.; Zhu Y.; Sun H.; Ma X.; Yang S.; Liu K.; OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. Int J Pharm 2018,537(1-2),172-182","journal-title":"Int J Pharm"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s11095-007-9453-7","volume":"24","author":"Uchida Y.","year":"2007","unstructured":"Uchida Y.; Kamiie J.; Ohtsuki S.; Terasaki T.; Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res 2007,24(12),2281-2296","journal-title":"Pharm Res"},{"key":"ref=83","first-page":"S-299","volume":"8","author":"Ganes D.","year":"1991","unstructured":"Ganes D.; Batra V.; Faulkner R.; Greene D.; Haynes J.; Kuye O.; Effect of probenecid on the pharmacokinetics of piperacillin and tazobactam in healthy volunteers. Proceedings of the Sixth Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Washington DC. Pharm Res 1991,8,S-299","journal-title":"Pharm Res"},{"key":"ref=84","year":"2017","unstructured":"Drug Information: Zosyn (piperacillin and tazobactam for injection) U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2017"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1124\/dmd.112.047068","volume":"40","author":"Warner D.J.","year":"2012","unstructured":"Warner D.J.; Chen H.; Cantin L.D.; Kenna J.G.; Stahl S.; Walker C.L.; Noeske T.; Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug Metab Dispos 2012,40(12),2332-2341","journal-title":"Drug Metab Dispos"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0002-9343(85)90127-5","volume":"79","author":"Scully B.E.","year":"1985","unstructured":"Scully B.E.; Chin N.X.; Neu H.C.; Pharmacology of ticarcillin combined with clavulanic acid in humans. Am J Med 1985,79(5B),39-43","journal-title":"Am J Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF00545973","volume":"23","author":"Davies B.E.","year":"1982","unstructured":"Davies B.E.; Humphrey M.J.; Langley P.F.; Lees L.; Legg B.; Wadds G.A.; Pharmacokinetics of ticarcillin in man. Eur J Clin Pharmacol 1982,23(2),167-172","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1128\/AAC.30.6.896","volume":"30","author":"Jungbluth G.L.","year":"1986","unstructured":"Jungbluth G.L.; Cooper D.L.; Doyle G.D.; Chudzik G.M.; Jusko W.J.; Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function. Antimicrob Agents Chemother 1986,30(6),896-900","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=89","year":"2014","unstructured":"Drug Information: Timentin (ticarcillin disodium and clavulanate potassium for injection) U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2014"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-642-14541-4_2","volume":"201","author":"Burckhardt G.","year":"2011","unstructured":"Burckhardt G.; Burckhardt B.C.; In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol 2011,201(201),29-104","journal-title":"Handb Exp Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"866","DOI":"10.2165\/00003495-199345060-00002","volume":"45","author":"Nathwani D.","year":"1993","unstructured":"Nathwani D.; Wood M.J.; Penicillins. A current review of their clinical pharmacology and therapeutic use. Drugs 1993,45(6),866-894","journal-title":"Drugs"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cpt196893345","volume":"9","author":"Gibaldi M.","year":"1968","unstructured":"Gibaldi M.; Schwartz M.A.; Apparent effect of probenecid on the distribution of penicillins in man. Clin Pharmacol Ther 1968,9(3),345-349","journal-title":"Clin Pharmacol Ther"},{"key":"ref=93","year":"2017","unstructured":"Drug Information: Penicillin G potassium injection Baxter Healthcare Corp U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2017","journal-title":"Baxter Healthcare Corp"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1124\/jpet.102.034330","volume":"302","author":"Takeda M.","year":"2002","unstructured":"Takeda M.; Khamdang S.; Narikawa S.; Kimura H.; Hosoyamada M.; Cha S.H.; Sekine T.; Endou H.; Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002,302(2),666-671","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1124\/dmd.113.055194","volume":"42","author":"Wang C.","year":"2014","unstructured":"Wang C.; Wang C.; Liu Q.; Meng Q.; Cang J.; Sun H.; Peng J.; Ma X.; Huo X.; Liu K.; Aspirin and probenecid inhibit organic anion transporter 3- mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos 2014,42(6),996-1007","journal-title":"Drug Metab Dispos"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1128\/AAC.33.9.1470","volume":"33","author":"Blum R.A.","year":"1989","unstructured":"Blum R.A.; Kohli R.K.; Harrison N.J.; Schentag J.J.; Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1989,33(9),1470-1476","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejpb.2004.07.008","volume":"59","author":"Luckner P.","year":"2005","unstructured":"Luckner P.; Brandsch M.; Interaction of 31 \u03b2-lactam antibiotics with the H+\/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm 2005,59(1),17-24","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.1970.00310040109013","volume":"125","author":"Kind A.C.","year":"1970","unstructured":"Kind A.C.; Tupasi T.E.; Standiford H.C.; Kirby W.M.; Mechanisms responsible for plasma levels of nafcillin lower than those of oxacillin. Arch Intern Med 1970,125(4),685-690","journal-title":"Arch Intern Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.1128\/AAC.02624-14","volume":"58","author":"Nesseler N.","year":"2014","unstructured":"Nesseler N.; Verdier M.C.; Launey Y.; Malherbe A.; Dermu M.; Piau C.; Fl\u00e9cher E.; Tribut O.; Mall\u00e9dant Y.; Seguin P.; High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery. Antimicrob Agents Chemother 2014,58(9),5448-5455","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1124\/dmd.112.049569","volume":"41","author":"Wolman A.T.","year":"2013","unstructured":"Wolman A.T.; Gionfriddo M.R.; Heindel G.A.; Mukhija P.; Witkowski S.; Bommareddy A.; Vanwert A.L.; Organic anion transporter 3 interacts selectively with lipophilic \u03b2-lactam antibiotics. Drug Metab Dispos 2013,41(4),791-800","journal-title":"Drug Metab Dispos"},{"key":"ref=101","year":"2017","unstructured":"Drug Information: Oxacillin injection Baxter Healthcare Corp U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2017","journal-title":"Baxter Healthcare Corp"},{"key":"ref=102","year":"2007","unstructured":"Drug Information: Geocillin (Carbenicillin indanyl sodium for oral use) Pfizer Inc U.S. Food and Drug AdministrationAvailable at:  https:\/\/www.fda.gov2007","journal-title":"Pfizer Inc"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1128\/AAC.01410-06","volume":"51","author":"Landersdorfer C.B.","year":"2007","unstructured":"Landersdorfer C.B.; Kirkpatrick C.M.; Kinzig-Schippers M.; Bulitta J.B.; Holzgrabe U.; Drusano G.L.; S\u00f6rgel F.; Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother 2007,51(9),3290-3297","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=104","first-page":"208","volume":"27","author":"Zheng H.","year":"2007","unstructured":"Zheng H.; Li H.M.; Fang S.X.; Pharmacokinetics of flucloxacillin sodium for injection. Chin Hosp Pharm J 2007,27,208-211","journal-title":"Chin Hosp Pharm J"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1124\/dmd.111.040758","volume":"40","author":"Dawson S.","year":"2012","unstructured":"Dawson S.; Stahl S.; Paul N.; Barber J.; Kenna J.G.; In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 2012,40(1),130-138","journal-title":"Drug Metab Dispos"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/BF00542548","volume":"22","author":"Thijssen H.H.","year":"1982","unstructured":"Thijssen H.H.; Wolters J.; The metabolic disposition of flucloxacillin in patients with impaired kidney function. Eur J Clin Pharmacol 1982,22(5),429-434","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/inf.1980.12.issue-3.10","volume":"12","author":"Hedstr\u00f6m S.A.","year":"1980","unstructured":"Hedstr\u00f6m S.A.; Kahlmeter G.; Dicloxacillin and flucloxacillin twice daily with probenecid in staphylococcal infections. A clinical and pharmakokinetic evaluation. Scand J Infect Dis 1980,12(3),221-225","journal-title":"Scand J Infect Dis"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/138920006775541534","volume":"7","author":"Huwyler J.","year":"2006","unstructured":"Huwyler J.; Wright M.B.; Gutmann H.; Drewe J.; Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drug Metab 2006,7(2),119-126","journal-title":"Curr Drug Metab"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jac\/4.suppl_B.69","volume":"4","author":"Schrogie J.J.","year":"1978","unstructured":"Schrogie J.J.; Davies R.O.; Yeh K.C.; Rogers D.; Holmes G.I.; Skeggs H.; Martin C.M.; Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother 1978,4(B),69-78","journal-title":"J Antimicrob Chemother"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1128\/AAC.17.5.847","volume":"17","author":"Vlasses P.H.","year":"1980","unstructured":"Vlasses P.H.; Holbrook A.M.; Schrogie J.J.; Rogers J.D.; Ferguson R.K.; Abrams W.B.; Effect of orally administered probenecid on the pharmacokinetics of cefoxitin. Antimicrob Agents Chemother 1980,17(5),847-855","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=111","first-page":"207","volume":"6","author":"Zhang Z.N.","year":"2015","unstructured":"Zhang Z.N.; Chen R.X.; Wang Y.F.; Liu Y.N.; Jiang Z.Z.; Interaction between drugs and gut microbiota. Chin Med Mater 2015,6,207-211","journal-title":"Chin Med Mater"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000222040","volume":"23","author":"Kirby W.M.","year":"1977","unstructured":"Kirby W.M.; Pharmacokinetics of fosfomycin. Chemotherapy 1977,23(Suppl. 1),141-151","journal-title":"Chemotherapy"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jac\/dkq070","volume":"65","author":"Matzi V.","year":"2010","unstructured":"Matzi V.; Lindenmann J.; Porubsky C.; Kugler S.A.; Maier A.; Dittrich P.; Smolle-J\u00fcttner F.M.; Joukhadar C.; Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 2010,65(5),995-998","journal-title":"J Antimicrob Chemother"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijantimicag.2013.05.018","volume":"42","author":"Parker S.","year":"2013","unstructured":"Parker S.; Lipman J.; Koulenti D.; Dimopoulos G.; Roberts J.A.; What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 2013,42(4),289-293","journal-title":"Int J Antimicrob Agents"},{"key":"ref=115","year":"1996","unstructured":"Drug Information: Amikacin (Amikacin sulfate for injection) Hospira Inc U.S. Food and Drug AdministrationAvailable at:  https:\/\/www.fda.gov1996","journal-title":"Hospira Inc"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1128\/AAC.02765-15","volume":"60","author":"Parvez M.M.","year":"2016","unstructured":"Parvez M.M.; Jung J.A.; Shin H.J.; Kim D.H.; Shin J.G.; Characterization of 22 antituberculosis drugs for inhibitory interaction potential on organic anionic transporter polypeptide (OATP)-mediated uptake. Antimicrob Agents Chemother 2016,60(5),3096-3105","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1128\/AAC.00907-16","volume":"60","author":"Gai Z.","year":"2016","unstructured":"Gai Z.; Visentin M.; Hiller C.; Krajnc E.; Li T.; Zhen J.; Kullak-Ublick G.A.; Organic cation transporter 2 overexpression may confer an increased risk of gentamicin-induced nephrotoxicity. Antimicrob Agents Chemother 2016,60(9),5573-5580","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1124\/jpet.106.104547","volume":"318","author":"Notenboom S.","year":"2006","unstructured":"Notenboom S.; Wouterse A.C.; Peters B.; Kuik L.H.; Heemskerk S.; Russel F.G.; Masereeuw R.; Increased apical insertion of the multidrug resistance protein 2 (MRP2\/ABCC2) in renal proximal tubules following gentamicin exposure. J Pharmacol Exp Ther 2006,318(3),1194-1202","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/AAC.32.1.92","volume":"32","author":"Boeckh M.","year":"1988","unstructured":"Boeckh M.; Lode H.; Borner K.; H\u00f6ffken G.; Wagner J.; Koeppe P.; Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother 1988,32(1),92-95","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=120","year":"2017","unstructured":"Drug Information: Vancocin (vancomycin hydrochloride for injection) ANI Pharmaceuticals, Inc U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2017","journal-title":"ANI Pharmaceuticals, Inc"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1124\/dmd.113.052548","volume":"41","author":"Pearce R.E.","year":"2013","unstructured":"Pearce R.E.; Cohen-Wolkowiez M.; Sampson M.R.; Kearns G.L.; The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos 2013,41(9),1686-1694","journal-title":"Drug Metab Dispos"},{"key":"ref=122","year":"2018","unstructured":"Drug Information: Metronidazole injection B Braun Medical Inc U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2018","journal-title":"B Braun Medical Inc"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJM197608122950702","volume":"295","author":"O\u2019Reilly R.A.","year":"1976","unstructured":"O\u2019Reilly R.A.; The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976,295(7),354-357","journal-title":"N Engl J Med"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejps.2018.01.002","volume":"115","author":"Lu X.","year":"2018","unstructured":"Lu X.; Chan T.; Zhu L.; Bao X.; Velkov T.; Zhou Q.T.; Li J.; Chan H.K.; Zhou F.; The inhibitory effects of eighteen front-line antibiotics on the substrate uptake mediated by human organic anion\/cation transporters, organic anion transporting polypeptides and oligopeptide transporters in in vitro models. Eur J Pharm Sci 2018,115,132-143","journal-title":"Eur J Pharm Sci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1124\/dmd.113.051235","volume":"41","author":"Du J.","year":"2013","unstructured":"Du J.; You T.; Chen X.; Zhong D.; Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. Drug Metab Dispos 2013,41(7),1306-1318","journal-title":"Drug Metab Dispos"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/clpt.1986.189","volume":"40","author":"Taburet A.M.","year":"1986","unstructured":"Taburet A.M.; Delion F.; Attali P.; Thebault J.J.; Singlas E.; Pharmacokinetics of ornidazole in patients with severe liver cirrhosis. Clin Pharmacol Ther 1986,40(3),359-364","journal-title":"Clin Pharmacol Ther"},{"key":"ref=127","year":"2018","unstructured":"Drug Information: Zyvox (Linezolid for injection) Pfizer, Inc U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2018","journal-title":"Pfizer, Inc"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/jac\/dkg180","volume":"51","author":"Stalker D.J.","year":"2003","unstructured":"Stalker D.J.; Jungbluth G.L.; Hopkins N.K.; Batts D.H.; Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003,51(5),1239-1246","journal-title":"J Antimicrob Chemother"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejps.2015.02.006","volume":"71","author":"Phillips O.A.","year":"2015","unstructured":"Phillips O.A.; Sharaf L.H.; D\u2019Silva R.; Udo E.E.; Benov L.; Evaluation of the monoamine oxidases inhibitory activity of a small series of 5-(azole)methyl oxazolidinones. Eur J Pharm Sci 2015,71,56-61","journal-title":"Eur J Pharm Sci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1128\/AAC.01151-16","volume":"60","author":"Parvez M.M.","year":"2016","unstructured":"Parvez M.M.; Kaisar N.; Shin H.J.; Jung J.A.; Shin J.G.; Inhibitory interaction potential of 22 antituberculosis drugs on organic anion and cation transporters of the SLC22A Family. Antimicrob Agents Chemother 2016,60(11),6558-6567","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=131","year":"2017","unstructured":"Drug Information: Cubicin (daptomycin for injection) Merck  U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2017","journal-title":"Merck"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/ndt\/gfp704","volume":"25","author":"Kielstein J.T.","year":"2010","unstructured":"Kielstein J.T.; Eugbers C.; Bode-Boeger S.M.; Martens-Lobenhoffer J.; Haller H.; Joukhadar C.; Traunm\u00fcller F.; Knitsch W.; Hafer C.; Burkhardt O.; Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant 2010,25(5),1537-1541","journal-title":"Nephrol Dial Transplant"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","volume":"47","author":"Dvorchik B.H.","year":"2003","unstructured":"Dvorchik B.H.; Brazier D.; DeBruin M.F.; Arbeit R.D.; Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003,47(4),1318-1323","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=134","first-page":"700","volume":"46","author":"Hu L.L.","year":"2015","unstructured":"Hu L.L.; Guo N.; Zhang X.L.; Shao H.; Determination of daptomycin by UPLC-MS \/MS and its pharmacokinetic evaluation in critically ill patients. Zhongguo Yaoke Daxue Xuebao 2015,46,700-706","journal-title":"Zhongguo Yaoke Daxue Xuebao"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1128\/AAC.41.10.2256","volume":"41","author":"Chien S.C.","year":"1997","unstructured":"Chien S.C.; Rogge M.C.; Gisclon L.G.; Curtin C.; Wong F.; Natarajan J.; Williams R.R.; Fowler C.L.; Cheung W.K.; Chow A.T.; Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997,41(10),2256-2260","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1592\/phco.22.15.1216.33484","volume":"22","author":"Rebuck J.A.","year":"2002","unstructured":"Rebuck J.A.; Fish D.N.; Abraham E.; Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 2002,22(10),1216-1225","journal-title":"Pharmacotherapy"},{"key":"ref=137","year":"2017","unstructured":"Drug Information: Levaquin (levofloxacin for injection) Janssen Pharmaceuticals, Inc U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2017","journal-title":"Janssen Pharmaceuticals, Inc"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2133\/dmpk.21.432","volume":"21","author":"Okuda M.","year":"2006","unstructured":"Okuda M.; Kimura N.; Inui K.; Interactions of fluoroquinolone antibacterials, DX-619 and levofloxacin, with creatinine transport by renal organic cation transporter hOCT2. Drug Metab Pharmacokinet 2006,21(5),432-436","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bcp.2007.04.010","volume":"74","author":"Tanihara Y.","year":"2007","unstructured":"Tanihara Y.; Masuda S.; Sato T.; Katsura T.; Ogawa O.; Inui K.; Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions\/H(+)-organic cation antiporters. Biochem Pharmacol 2007,74(2),359-371","journal-title":"Biochem Pharmacol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1124\/mol.116.105056","volume":"90","author":"Mart\u00ednez-Guerrero L.J.","year":"2016","unstructured":"Mart\u00ednez-Guerrero L.J.; Morales M.; Ekins S.; Wright S.H.; Lack of influence of substrate on ligand interaction with the human multidrug and toxin extruder, MATE1. Mol Pharmacol 2016,90(3),254-264","journal-title":"Mol Pharmacol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1128\/AAC.36.5.993","volume":"36","author":"Lettieri J.T.","year":"1992","unstructured":"Lettieri J.T.; Rogge M.C.; Kaiser L.; Echols R.M.; Heller A.H.; Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992,36(5),993-996","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2125.2009.03564.x","volume":"69","author":"Landersdorfer C.B.","year":"2010","unstructured":"Landersdorfer C.B.; Kirkpatrick C.M.; Kinzig M.; Bulitta J.B.; Holzgrabe U.; Jaehde U.; Reiter A.; Naber K.G.; Rodamer M.; S\u00f6rgel F.; Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. Br J Clin Pharmacol 2010,69(2),167-178","journal-title":"Br J Clin Pharmacol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1124\/dmd.115.065193","volume":"43","author":"Goldman J.L.","year":"2015","unstructured":"Goldman J.L.; Leeder J.S.; Van Haandel L.; Pearce R.E.; In vitro hepatic oxidative biotransformation of trimethoprim. Drug Metab Dispos 2015,43(9),1372-1380","journal-title":"Drug Metab Dispos"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/j.1745-7254.2008.00908.x","volume":"29","author":"Zhang L.","year":"2008","unstructured":"Zhang L.; Wei M.J.; Zhao C.Y.; Qi H.M.; Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin 2008,29(12),1507-1514","journal-title":"Acta Pharmacol Sin"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2125.1995.tb04453.x","volume":"39","author":"Batty K.T.","year":"1995","unstructured":"Batty K.T.; Davis T.M.; Ilett K.F.; Dusci L.J.; Langton S.R.; The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995,39(3),305-311","journal-title":"Br J Clin Pharmacol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s002280000192","volume":"56","author":"Raaska K.","year":"2000","unstructured":"Raaska K.; Neuvonen P.J.; Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000,56(8),585-589","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.clpt.2004.08.018","volume":"76","author":"Granfors M.T.","year":"2004","unstructured":"Granfors M.T.; Backman J.T.; Neuvonen M.; Neuvonen P.J.; Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004,76(6),598-606","journal-title":"Clin Pharmacol Ther"},{"key":"ref=148","year":"2017","unstructured":"Drug Information: Cipro IV (Ciprofloxacin for injection) Bayer Health Care U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2017","journal-title":"Bayer Health Care"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1124\/dmd.109.027441","volume":"37","author":"Senggunprai L.","year":"2009","unstructured":"Senggunprai L.; Yoshinari K.; Yamazoe Y.; Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans. Drug Metab Dispos 2009,37(8),1711-1717","journal-title":"Drug Metab Dispos"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jac\/43.suppl_2.83","volume":"43","author":"Stass H.","year":"1999","unstructured":"Stass H.; Kubitza D.; Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999,43(Suppl. B),83-90","journal-title":"J Antimicrob Chemother"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1124\/dmd.104.003178","volume":"33","author":"Tachibana M.","year":"2005","unstructured":"Tachibana M.; Tanaka M.; Masubuchi Y.; Horie T.; Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab Dispos 2005,33(6),803-811","journal-title":"Drug Metab Dispos"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1128\/AAC.01471-16","volume":"60","author":"Te Brake L.H.","year":"2016","unstructured":"Te Brake L.H.; van den Heuvel J.J.; Buaben A.O.; van Crevel R.; Bilos A.; Russel F.G.; Aarnoutse R.E.; Koenderink J.B.; Moxifloxacin is a potent in vitro inhibitor of OCT-and MATE-mediated transport of metformin and ethambutol. Antimicrob Agents Chemother 2016,60(12),7105-7114","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40262-015-0332-9","volume":"55","author":"Morrissey K.M.","year":"2016","unstructured":"Morrissey K.M.; Stocker S.L.; Chen E.C.; Castro R.A.; Brett C.M.; Giacomini K.M.; The effect of nizatidine, a MATE2K selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin in healthy volunteers. Clin Pharmacokinet 2016,55(4),495-506","journal-title":"Clin Pharmacokinet"},{"key":"ref=154","year":"2016","unstructured":"Drug Information: Avelox (moxifloxacin hydrochloride for injection) Merck  U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2016","journal-title":"Merck"},{"key":"ref=155","first-page":"502","volume":"25","author":"Wang R.W.","year":"1997","unstructured":"Wang R.W.; Newton D.J.; Scheri T.D.; Lu A.Y.; Human cytochrome P450 3A4-catalyzed testosterone 6 \u03b2-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab Dispos 1997,25(4),502-507","journal-title":"Drug Metab Dispos"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1124\/dmd.104.001313","volume":"32","author":"Huang W.","year":"2004","unstructured":"Huang W.; Lin Y.S.; McConn D.J.; Calamia J.C.; Totah R.A.; Isoherranen N.; Glodowski M.; Thummel K.E.; Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004,32(12),1434-1445","journal-title":"Drug Metab Dispos"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/clpt.1993.25","volume":"53","author":"Olkkola K.T.","year":"1993","unstructured":"Olkkola K.T.; Aranko K.; Luurila H.; Hiller A.; Saarnivaara L.; Himberg J.J.; Neuvonen P.J.; A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993,53(3),298-305","journal-title":"Clin Pharmacol Ther"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/j.1552-4604.1982.tb02682.x","volume":"22","author":"Hall K.W.","year":"1982","unstructured":"Hall K.W.; Nightingale C.H.; Gibaldi M.; Nelson E.; Bates T.R.; DiSanto A.R.; Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects. J Clin Pharmacol 1982,22(7),321-325","journal-title":"J Clin Pharmacol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/clpt.2012.106","volume":"92","author":"Lancaster C.S.","year":"2012","unstructured":"Lancaster C.S.; Bruun G.H.; Peer C.J.; Mikkelsen T.S.; Corydon T.J.; Gibson A.A.; Hu S.; Orwick S.J.; Mathijssen R.H.J.; Figg W.D.; Baker S.D.; Sparreboom A.; OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther 2012,92(5),642-650","journal-title":"Clin Pharmacol Ther"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/clpt.2011.25","volume":"89","author":"Franke R.M.","year":"2011","unstructured":"Franke R.M.; Lancaster C.S.; Peer C.J.; Gibson A.A.; Kosloske A.M.; Orwick S.J.; Mathijssen R.H.J.; Figg W.D.; Baker S.D.; Sparreboom A.; Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther 2011,89(5),693-701","journal-title":"Clin Pharmacol Ther"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/dmd.110.034629","volume":"39","author":"Lin X.","year":"2011","unstructured":"Lin X.; Skolnik S.; Chen X.; Wang J.; Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. Drug Metab Dispos 2011,39(2),265-274","journal-title":"Drug Metab Dispos"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1124\/dmd.104.003301","volume":"33","author":"Kobayashi Y.","year":"2005","unstructured":"Kobayashi Y.; Sakai R.; Ohshiro N.; Ohbayashi M.; Kohyama N.; Yamamoto T.; Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos 2005,33(5),619-622","journal-title":"Drug Metab Dispos"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1124\/dmd.108.022178","volume":"37","author":"Zhang X.","year":"2009","unstructured":"Zhang X.; Jones D.R.; Hall S.D.; Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 2009,37(1),150-160","journal-title":"Drug Metab Dispos"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1124\/dmd.32.10.1083","volume":"32","author":"McConn D.J.","year":"2004","unstructured":"McConn D.J.; Lin Y.S.; Allen K.; Kunze K.L.; Thummel K.E.; Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 2004,32(10),1083-1091","journal-title":"Drug Metab Dispos"},{"key":"ref=165","first-page":"776","volume":"23","author":"Freeman D.J.","year":"1987","unstructured":"Freeman D.J.; Martell R.; Carruthers S.G.; Heinrichs D.; Keown P.A.; Stiller C.R.; Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol 1987,23(6),776-778","journal-title":"Br J Clin Pharmacol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(94)92383-3","volume":"344","author":"Jensen C.","year":"1994","unstructured":"Jensen C.; Jordan M.; Shapiro R.; Scantlebury V.; Hakala T.; Fung J.; Starzl T.; Venkataramanan R.; Interaction between tacrolimus and erythromycin. Lancet 1994,344(8925),825","journal-title":"Lancet"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1124\/dmd.106.009290","volume":"34","author":"Hirano M.","year":"2006","unstructured":"Hirano M.; Maeda K.; Shitara Y.; Sugiyama Y.; Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006,34(7),1229-1236","journal-title":"Drug Metab Dispos"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1124\/mol.112.084152","volume":"83","author":"De Bruyn T.","year":"2013","unstructured":"De Bruyn T.; van Westen G.J.; Ijzerman A.P.; Stieger B.; de Witte P.; Augustijns P.F.; Annaert P.P.; Structure-based identification of OATP1B1\/3 inhibitors. Mol Pharmacol 2013,83(6),1257-1267","journal-title":"Mol Pharmacol"},{"key":"ref=169","year":"2013","unstructured":"Drug Information: Erythrocin (erythromycin lactobionate for injection) Hospira, Inc U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2013","journal-title":"Hospira, Inc"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1124\/dmd.31.7.878","volume":"31","author":"Wynalda M.A.","year":"2003","unstructured":"Wynalda M.A.; Hutzler J.M.; Koets M.D.; Podoll T.; Wienkers L.C.; In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos 2003,31(7),878-887","journal-title":"Drug Metab Dispos"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","volume":"49","author":"Muralidharan G.","year":"2005","unstructured":"Muralidharan G.; Micalizzi M.; Speth J.; Raible D.; Troy S.; Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005,49(1),220-229","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1124\/dmd.107.015735","volume":"35","author":"Hoffmann M.","year":"2007","unstructured":"Hoffmann M.; DeMaio W.; Jordan R.A.; Talaat R.; Harper D.; Speth J.; Scatina J.; Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007,35(9),1543-1553","journal-title":"Drug Metab Dispos"},{"key":"ref=173","year":"2018","unstructured":"Drug Information: Tygacil (Tigecycline for injection) Wyeth Pharmaceuticals, LLC U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2018","journal-title":"Wyeth Pharmaceuticals, LLC"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1592\/phco.28.7.895","volume":"28","author":"Zimmerman J.J.","year":"2008","unstructured":"Zimmerman J.J.; Raible D.G.; Harper D.M.; Matschke K.; Speth J.L.; Evaluation of a potential tigecycline-warfarin drug interaction. Pharmacotherapy 2008,28(7),895-905","journal-title":"Pharmacotherapy"},{"key":"ref=175","year":"2018","unstructured":"Drug Information: Bactrim (sulfamethoxazole and trimethoprim for injection) Sun Pharmaceutical Industries, Inc U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2018","journal-title":"Sun Pharmaceutical Industries, Inc"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/0006-2952(93)90280-A","volume":"45","author":"Cribb A.E.","year":"1993","unstructured":"Cribb A.E.; Nakamura H.; Grant D.M.; Miller M.A.; Spielberg S.P.; Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem Pharmacol 1993,45(6),1277-1282","journal-title":"Biochem Pharmacol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1365-2125.2003.02027.x","volume":"57","author":"Niemi M.","year":"2004","unstructured":"Niemi M.; Kajosaari L.I.; Neuvonen M.; Backman J.T.; Neuvonen P.J.; The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004,57(4),441-447","journal-title":"Br J Clin Pharmacol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/dmd.107.018010","volume":"36","author":"Tornio A.","year":"2008","unstructured":"Tornio A.; Niemi M.; Neuvonen P.J.; Backman J.T.; Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008,36(1),73-80","journal-title":"Drug Metab Dispos"},{"key":"ref=179","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.357","volume":"5","author":"Elsby R.","year":"2017","unstructured":"Elsby R.; Chidlaw S.; Outteridge S.; Pickering S.; Radcliffe A.; Sullivan R.; Jones H.; Butler P.; Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. Pharmacol Res Perspect 2017,5(5)","journal-title":"Pharmacol Res Perspect"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJM198001033020106","volume":"302","author":"O\u2019Reilly R.A.","year":"1980","unstructured":"O\u2019Reilly R.A.; Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980,302(1),33-35","journal-title":"N Engl J Med"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archinternmed.2010.37","volume":"170","author":"Fischer H.D.","year":"2010","unstructured":"Fischer H.D.; Juurlink D.N.; Mamdani M.M.; Kopp A.; Laupacis A.; Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 2010,170(7),617-621","journal-title":"Arch Intern Med"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1124\/dmd.30.6.631","volume":"30","author":"Wen X.","year":"2002","unstructured":"Wen X.; Wang J.S.; Backman J.T.; Laitila J.; Neuvonen P.J.; Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002,30(6),631-635","journal-title":"Drug Metab Dispos"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.0954-6820.1979.tb00729.x","volume":"624","author":"Hansen J.M.","year":"1979","unstructured":"Hansen J.M.; Kampmann J.P.; Siersbaek-Nielsen K.; Lumholtz I.B.; Arr\u00f8e M.; Abildgaard U.; Skovsted L.; The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl 1979,624,106-110","journal-title":"Acta Med Scand Suppl"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.clpt.2004.05.001","volume":"76","author":"Niemi M.","year":"2004","unstructured":"Niemi M.; Backman J.T.; Neuvonen P.J.; Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 2004,76(3),239-249","journal-title":"Clin Pharmacol Ther"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejps.2017.03.002","volume":"103","author":"Pedersen J.M.","year":"2017","unstructured":"Pedersen J.M.; Khan E.K.; Bergstr\u00f6m C.A.S.; Palm J.; Hoogstraate J.; Artursson P.; Substrate and method dependent inhibition of three ABC-transporters (MDR1, BCRP, and MRP2). Eur J Pharm Sci 2017,103,70-76","journal-title":"Eur J Pharm Sci"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/bdd.749","volume":"32","author":"Choi M.K.","year":"2011","unstructured":"Choi M.K.; Jin Q.R.; Choi Y.L.; Ahn S.H.; Bae M.A.; Song I.S.; Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. Biopharm Drug Dispos 2011,32(3),175-184","journal-title":"Biopharm Drug Dispos"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"Niemi M.","year":"2003","unstructured":"Niemi M.; Backman J.T.; Fromm M.F.; Neuvonen P.J.; Kivist\u00f6 K.T.; Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003,42(9),819-850","journal-title":"Clin Pharmacokinet"},{"key":"ref=188","year":"2018","unstructured":"Drug Information: Rifadin IV (rifampin for injection) Sanofi-aventis US LLC U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2018","journal-title":"Sanofi-aventis US LLC"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1211\/0022357011775488","volume":"53","author":"Jaruratanasirikul S.","year":"2001","unstructured":"Jaruratanasirikul S.; Sriwiriyajan S.; Effect of indinavir on the pharmacokinetics of rifampicin in HIV-infected patients. J Pharm Pharmacol 2001,53(3),409-412","journal-title":"J Pharm Pharmacol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/clpt.2008.186","volume":"85","author":"Zheng H.X.","year":"2009","unstructured":"Zheng H.X.; Huang Y.; Frassetto L.A.; Benet L.Z.; Elucidating rifampin\u2019s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 2009,85(1),78-85","journal-title":"Clin Pharmacol Ther"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00204-008-0317-7","volume":"82","author":"Westerink W.M.","year":"2008","unstructured":"Westerink W.M.; Stevenson J.C.; Schoonen W.G.; Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol 2008,82(12),909-921","journal-title":"Arch Toxicol"},{"key":"ref=192","first-page":"849","volume":"299","author":"Rae J.M.","year":"2001","unstructured":"Rae J.M.; Johnson M.D.; Lippman M.E.; Flockhart D.A.; Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001,299(3),849-857","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1124\/dmd.107.016089","volume":"35","author":"Dixit V.","year":"2007","unstructured":"Dixit V.; Hariparsad N.; Li F.; Desai P.; Thummel K.E.; Unadkat J.D.; Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007,35(10),1853-1859","journal-title":"Drug Metab Dispos"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2125.1985.tb05071.x","volume":"20","author":"Kay L.","year":"1985","unstructured":"Kay L.; Kampmann J.P.; Svendsen T.L.; Vergman B.; Hansen J.E.; Skovsted L.; Kristensen M.; Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 1985,20(4),323-326","journal-title":"Br J Clin Pharmacol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1177\/0091270005279580","volume":"45","author":"Hebert M.F.","year":"2005","unstructured":"Hebert M.F.; Smith H.E.; Marbury T.C.; Swan S.K.; Smith W.B.; Townsend R.W.; Buell D.; Keirns J.; Bekersky I.; Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005,45(10),1145-1152","journal-title":"J Clin Pharmacol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1124\/dmd.110.033811","volume":"38","author":"Yanni S.B.","year":"2010","unstructured":"Yanni S.B.; Augustijns P.F.; Benjamin D.K.; Brouwer K.L.; Thakker D.R.; Annaert P.P.; In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. Drug Metab Dispos 2010,38(10),1848-1856","journal-title":"Drug Metab Dispos"},{"key":"ref=197","year":"2016","unstructured":"Drug Information: Mycamine (micafungin sodium for injection) Astellas Pharma Tech Co Ltd U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2016","journal-title":"Astellas Pharma Tech Co Ltd"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1128\/AAC.00623-15","volume":"59","author":"Lempers V.J.","year":"2015","unstructured":"Lempers V.J.; Schouten J.A.; Hunfeld N.G.; Colbers A.; van Leeuwen H.J.; Burger D.M.; Verweij P.E.; Pickkers P.; Br\u00fcggemann R.J.; Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother 2015,59(8),4403-4409","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jac\/dkw352","volume":"72","author":"Jullien V.","year":"2017","unstructured":"Jullien V.; Azoulay E.; Schwebel C.; Le Saux T.; Charles P.E.; Cornet M.; Souweine B.; Klouche K.; Jaber S.; Trouillet J.L.; Bruneel F.; Cour M.; Cousson J.; Meziani F.; Gruson D.; Paris A.; Darmon M.; Garrouste-Orgeas M.; Navellou J.C.; Foucrier A.; Allaouchiche B.; Das V.; Gangneux J.P.; Ruckly S.; Wolff M.; Timsit J.F.; Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. J Antimicrob Chemother 2017,72(1),181-189","journal-title":"J Antimicrob Chemother"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","volume":"46","author":"Stone J.A.","year":"2002","unstructured":"Stone J.A.; Holland S.D.; Wickersham P.J.; Sterrett A.; Schwartz M.; Bonfiglio C.; Hesney M.; Winchell G.A.; Deutsch P.J.; Greenberg H.; Hunt T.L.; Waldman S.A.; Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002,46(3),739-745","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1128\/AAC.48.11.4306-4314.2004","volume":"48","author":"Stone J.A.","year":"2004","unstructured":"Stone J.A.; Migoya E.M.; Hickey L.; Winchell G.A.; Deutsch P.J.; Ghosh K.; Freeman A.; Bi S.; Desai R.; Dilzer S.C.; Lasseter K.C.; Kraft W.K.; Greenberg H.; Waldman S.A.; Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004,48(11),4306-4314","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1128\/AAC.48.3.815-823.2004","volume":"48","author":"Stone J.A.","year":"2004","unstructured":"Stone J.A.; Xu X.; Winchell G.A.; Deutsch P.J.; Pearson P.G.; Migoya E.M.; Mistry G.C.; Xi L.; Miller A.; Sandhu P.; Singh R.; deLuna F.; Dilzer S.C.; Lasseter K.C.; Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004,48(3),815-823","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1093\/jac\/dku313","volume":"69","author":"Muilwijk E.W.","year":"2014","unstructured":"Muilwijk E.W.; Schouten J.A.; van Leeuwen H.J.; van Zanten A.R.; de Lange D.W.; Colbers A.; Verweij P.E.; Burger D.M.; Pickkers P.; Br\u00fcggemann R.J.; Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother 2014,69(12),3294-3299","journal-title":"J Antimicrob Chemother"},{"key":"ref=204","year":"2018","unstructured":"Drug Information: Cancidas (caspofungin acetate for injection) Merck Sharp  U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2018","journal-title":"Merck Sharp"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/10245330410001701585","volume":"9","author":"Colburn D.E.","year":"2004","unstructured":"Colburn D.E.; Giles F.J.; Oladovich D.; Smith J.A.; In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004,9(3),217-221","journal-title":"Hematology"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","volume":"46","author":"Bekersky I.","year":"2002","unstructured":"Bekersky I.; Fielding R.M.; Dressler D.E.; Lee J.W.; Buell D.N.; Walsh T.J.; Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002,46(3),828-833","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1128\/AAC.41.6.1275","volume":"41","author":"Heinemann V.","year":"1997","unstructured":"Heinemann V.; Bosse D.; Jehn U.; K\u00e4hny B.; Wachholz K.; Debus A.; Scholz P.; Kolb H.J.; Wilmanns W.; Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob Agents Chemother 1997,41(6),1275-1280","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=208","year":"2014","unstructured":"Drug Information: Diflucan (fluconazole for injection) Pfizer Inc U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2014","journal-title":"Pfizer Inc"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1248\/bpb.28.1805","volume":"28","author":"Niwa T.","year":"2005","unstructured":"Niwa T.; Shiraga T.; Takagi A.; Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005,28(9),1805-1808","journal-title":"Biol Pharm Bull"},{"key":"ref=210","first-page":"422","volume":"24","author":"Black D.J.","year":"1996","unstructured":"Black D.J.; Kunze K.L.; Wienkers L.C.; Gidal B.E.; Seaton T.L.; McDonnell N.D.; Evans J.S.; Bauwens J.E.; Trager W.F.; Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996,24(4),422-428","journal-title":"Drug Metab Dispos"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s002280000127","volume":"56","author":"Kantola T.","year":"2000","unstructured":"Kantola T.; Backman J.T.; Niemi M.; Kivist\u00f6 K.T.; Neuvonen P.J.; Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000,56(3),225-229","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s002280050223","volume":"51","author":"Ahonen J.","year":"1997","unstructured":"Ahonen J.; Olkkola K.T.; Neuvonen P.J.; Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997,51(5),415-419","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00228-007-0350-0","volume":"63","author":"Saari T.I.","year":"2007","unstructured":"Saari T.I.; Laine K.; Bertilsson L.; Neuvonen P.J.; Olkkola K.T.; Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007,63(10),941-949","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1124\/dmd.107.018382","volume":"36","author":"Isoherranen N.","year":"2008","unstructured":"Isoherranen N.; Ludington S.R.; Givens R.C.; Lamba J.K.; Pusek S.N.; Dees E.C.; Blough D.K.; Iwanaga K.; Hawke R.L.; Schuetz E.G.; Watkins P.B.; Thummel K.E.; Paine M.F.; The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos 2008,36(1),146-154","journal-title":"Drug Metab Dispos"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/jat\/bkv030","volume":"39","author":"Moody D.E.","year":"2015","unstructured":"Moody D.E.; Liu F.; Fang W.B.; Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism. J Anal Toxicol 2015,39(5),374-386","journal-title":"J Anal Toxicol"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.xphs.2016.01.007","volume":"105","author":"Niwa T.","year":"2016","unstructured":"Niwa T.; Hata T.; The effect of genetic polymorphism on the inhibition of azole antifungal agents against CYP2C9-mediated metabolism. J Pharm Sci 2016,105(3),1345-1348","journal-title":"J Pharm Sci"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3109\/00498254.2011.582893","volume":"41","author":"Wang H.","year":"2011","unstructured":"Wang H.; Kim R.A.; Sun D.; Gao Y.; Wang H.; Zhu J.; Chen C.; Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Xenobiotica 2011,41(9),826-835","journal-title":"Xenobiotica"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","volume":"61","author":"Uchaipichat V.","year":"2006","unstructured":"Uchaipichat V.; Winner L.K.; Mackenzie P.I.; Elliot D.J.; Williams J.A.; Miners J.O.; Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 2006,61(4),427-439","journal-title":"Br J Clin Pharmacol"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1128\/AAC.00630-06","volume":"50","author":"Mouton J.W.","year":"2006","unstructured":"Mouton J.W.; van Peer A.; de Beule K.; Van Vliet A.; Donnelly J.P.; Soons P.A.; Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006,50(12),4096-4102","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=220","year":"2009","unstructured":"Drug Information: Sporanox (itraconazole for injection) Hospira, Inc U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2009","journal-title":"Hospira, Inc"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2165\/00002018-199309040-00008","volume":"9","author":"Bonay M.","year":"1993","unstructured":"Bonay M.; Jonville-Bera A.P.; Diot P.; Lemarie E.; Lavandier M.; Autret E.; Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993,9(4),309-311","journal-title":"Drug Saf"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/clinids\/18.2.266","volume":"18","author":"Drayton J.","year":"1994","unstructured":"Drayton J.; Dickinson G.; Rinaldi M.G.; Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994,18(2),266","journal-title":"Clin Infect Dis"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1124\/dmd.115.067744","volume":"44","author":"Vermeer L.M.","year":"2016","unstructured":"Vermeer L.M.; Isringhausen C.D.; Ogilvie B.W.; Buckley D.B.; Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters. Drug Metab Dispos 2016,44(3),453-459","journal-title":"Drug Metab Dispos"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1124\/dmd.110.032094","volume":"38","author":"Foti R.S.","year":"2010","unstructured":"Foti R.S.; Rock D.A.; Wienkers L.C.; Wahlstrom J.L.; Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 2010,38(6),981-987","journal-title":"Drug Metab Dispos"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1177\/0091270006293753","volume":"46","author":"Walsky R.L.","year":"2006","unstructured":"Walsky R.L.; Astuccio A.V.; Obach R.S.; Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 2006,46(12),1426-1438","journal-title":"J Clin Pharmacol"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1124\/dmd.111.043117","volume":"40","author":"Walsky R.L.","year":"2012","unstructured":"Walsky R.L.; Bauman J.N.; Bourcier K.; Giddens G.; Lapham K.; Negahban A.; Ryder T.F.; Obach R.S.; Hyland R.; Goosen T.C.; Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos 2012,40(5),1051-1065","journal-title":"Drug Metab Dispos"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","volume":"46","author":"Purkins L.","year":"2002","unstructured":"Purkins L.; Wood N.; Ghahramani P.; Greenhalgh K.; Allen M.J.; Kleinermans D.; Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002,46(8),2546-2553","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.31.5.540","volume":"31","author":"Hyland R.","year":"2003","unstructured":"Hyland R.; Jones B.C.; Smith D.A.; Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003,31(5),540-547","journal-title":"Drug Metab Dispos"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1128\/AAC.01123-08","volume":"53","author":"Jeong S.","year":"2009","unstructured":"Jeong S.; Nguyen P.D.; Desta Z.; Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 2009,53(2),541-551","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijantimicag.2006.01.003","volume":"27","author":"Lev\u00eaque D.","year":"2006","unstructured":"Lev\u00eaque D.; Nivoix Y.; Jehl F.; Herbrecht R.; Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006,27(4),274-284","journal-title":"Int J Antimicrob Agents"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1128\/AAC.00579-07","volume":"51","author":"Geist M.J.","year":"2007","unstructured":"Geist M.J.; Egerer G.; Burhenne J.; Riedel K.D.; Mikus G.; Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother 2007,51(9),3455-3456","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1128\/AAC.00526-07","volume":"51","author":"Liu P.","year":"2007","unstructured":"Liu P.; Foster G.; Gandelman K.; LaBadie R.R.; Allison M.J.; Gutierrez M.J.; Sharma A.; Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007,51(10),3617-3626","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1124\/dmd.111.042416","volume":"40","author":"Xu C.","year":"2012","unstructured":"Xu C.; Ogburn E.T.; Guo Y.; Desta Z.; Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos 2012,40(4),717-725","journal-title":"Drug Metab Dispos"},{"key":"ref=234","year":"2017","unstructured":"Drug Information: Vfend (voriconazole for injection) Pfizer Inc U.S. Food and Drug AdministrationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.pharmapendium.com\">http:\/\/www.pharmapendium.com2017","journal-title":"Pfizer Inc"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","volume":"79","author":"Saari T.I.","year":"2006","unstructured":"Saari T.I.; Laine K.; Leino K.; Valtonen M.; Neuvonen P.J.; Olkkola K.T.; Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006,79(4),362-370","journal-title":"Clin Pharmacol Ther"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.0306-5251.2001.temp.1441.x","volume":"52","author":"Tucker G.T.","year":"2001","unstructured":"Tucker G.T.; Houston J.B.; Huang S.M.; Optimizing drug development: strategies to assess drug metabolism\/transporter interaction potential-towards a consensus. Br J Clin Pharmacol 2001,52(1),107-117","journal-title":"Br J Clin Pharmacol"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/186382","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186382\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/186382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T16:45:14Z","timestamp":1632501914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186382\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":236,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3,22]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221666200929115117","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}